CGRP Inhibitors Within the Migraine Treatment Landscape
An Interactive Learning Experience Sponsored by Amgen and Novartis; Not for CME/CE Credit This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
This interactive learning experience is powered by Amplifire. They use brain science and an adaptive algorithm that adjusts the experience to tailor content to meet your learning needs. Here’s how it’s different: you will be asked questions before you start learning. Research shows that answering questions prepares your brain to learn, and it helps make new concepts stick. In addition, the questions are used to customize your experience.
Migraine is more than just a headache–it is a complex and multifaceted neurological disease.1-3 Recent breakthroughs in drug development are offering patients with migraine more options to better manage their disease.
This “CGRP Inhibitors Within the Migraine Treatment Landscape” module provides an overview of current strategies on management so you can reinforce and expand upon your knowledge of the treatments available for your patients.
This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.
By the end of this module, you will improve your understanding of:
AHS, American Headache Society; CGRP, calcitonin gene-related peptide.
© 2021 Amgen Inc. All rights reserved. USA-334-83841